<br>6-（4-苯基哌嗪-1-基）吡啶-3-羧昔酰胺和化学类似物对 C1s 蛋白酶和经典补体途径的抑制,The Journal of Immunology

当前位置： X-MOL 学术 › J. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

6-（4-苯基哌嗪-1-基）吡啶-3-羧昔酰胺和化学类似物对 C1s 蛋白酶和经典补体途径的抑制
The Journal of Immunology ( IF 3.6 ) Pub Date : 2023-12-27 , DOI: 10.4049/jimmunol.2300630
Xin Xu ₁ , Timothy J Herdendorf ₁ , Huiquan Duan ₁ , Denise L Rohlik ₂ , Sourav Roy ₂ , Hinman Zhou ₃ , Haya Alkhateeb ₃ , Sanjay Khandelwal ₄ , Qilong Zhou ₅ , Ping Li ₅ , Gowthami M Arepally ₄ , John K Walker _{3,

6} , Brandon L Garcia ₂ , Brian V Geisbrecht ₁

Affiliation

摘要经典途径（CP）是启动补体活性的有效机制，是许多补体介导的疾病的病理驱动因素。CP 是通过激活补体成分 C1 启动的，补体成分 C1 由与蛋白酶 C1r 和 C1s 的四聚体组装结合的模式识别分子 C1q 组成。酶活性 C1s 为下游 CP 成分 C4 和 C2 的切割提供了催化基础，因此是 CP 驱动疾病治疗干预的有吸引力的靶标。尽管 FDA 已批准抗 C1s mAb，但鉴定小分子 C1s 抑制剂仍是重中之重。在这项研究中，我们将 6-（4-苯基哌嗪-1-基）吡啶-3-羧酰酰胺（A1）描述为 C1s 的选择性竞争性抑制剂。A1 是通过虚拟筛选与 C1s 底物识别位点相互作用的小分子来识别的。随后的功能研究表明，A1 剂量依赖性地抑制肝素诱导的免疫复合物的 CP 激活、CP 驱动的 Ab 致敏绵羊红细胞裂解、通路特异性 ELISA 中的 CP 激活以及 C1 裂解 C2。生化实验表明，A1 以 ∼9.8 μM 的 Kd 直接与 C1 结合，并以 ∼5.8 μM 的抑制常数（Ki）竞争性抑制其活性。1.8 Å 分辨率的晶体结构揭示了 A1 抑制 C1s 的物理基础，并提供了有关 A1 支架的结构-活性关系的信息，这得到了一组 A1 类似物评估的支持。综上所述，我们的工作将 A1 确定为一类新的小分子 C1s 抑制剂，并为开发越来越有效和选择性的 A1 类似物奠定了基础，用于研究和治疗目的。

"点击查看英文标题和摘要"

Inhibition of the C1s Protease and the Classical Complement Pathway by 6-(4-Phenylpiperazin-1-yl)Pyridine-3-Carboximidamide and Chemical Analogs

Abstract The classical pathway (CP) is a potent mechanism for initiating complement activity and is a driver of pathology in many complement-mediated diseases. The CP is initiated via activation of complement component C1, which consists of the pattern recognition molecule C1q bound to a tetrameric assembly of proteases C1r and C1s. Enzymatically active C1s provides the catalytic basis for cleavage of the downstream CP components, C4 and C2, and is therefore an attractive target for therapeutic intervention in CP-driven diseases. Although an anti-C1s mAb has been Food and Drug Administration approved, identifying small-molecule C1s inhibitors remains a priority. In this study, we describe 6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide (A1) as a selective, competitive inhibitor of C1s. A1 was identified through a virtual screen for small molecules that interact with the C1s substrate recognition site. Subsequent functional studies revealed that A1 dose-dependently inhibits CP activation by heparin-induced immune complexes, CP-driven lysis of Ab-sensitized sheep erythrocytes, CP activation in a pathway-specific ELISA, and cleavage of C2 by C1s. Biochemical experiments demonstrated that A1 binds directly to C1s with a Kd of ∼9.8 μM and competitively inhibits its activity with an inhibition constant (Ki) of ∼5.8 μM. A 1.8-Å-resolution crystal structure revealed the physical basis for C1s inhibition by A1 and provided information on the structure–activity relationship of the A1 scaffold, which was supported by evaluating a panel of A1 analogs. Taken together, our work identifies A1 as a new class of small-molecule C1s inhibitor and lays the foundation for development of increasingly potent and selective A1 analogs for both research and therapeutic purposes.

更新日期：2023-12-27

点击分享查看原文

点击收藏

阅读更多本刊新发论文